Quinoxaline derivatives as pi3 kinase inhibitors

A compound of Formula (I)(G):

• in which
• each R2, R3, R4 and R5 is independently selected from:
• hydrogen, halogen, acyl, amino, substituted amino, arylamino, acylamino, heterocycloalkylamino, C1-6alkyl, substituted C1-6alkyl, C3-7cycloalkyl, substituted C3-7cycloalkyl, C3-7heterocycloalkyl, substituted C3-7heterocycloalkyl, alkylcarboxy, aminoalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, arylcycloalkyl, substituted arylcycloalkyl, heteroarylalkyl, substituted heteroarylalkyl, cyano, hydroxyl, alkoxy, acyloxy, and aryloxy;
• or R5 is R6, wherein R6 is —SO2NR80 or —NSO2R80, in which R80 is selected from a group consisting of:
• C1-C6alkyl, C1-C6cycloalkyl, C1-C6heterocycloalkyl, substituted C1-C6alkyl, substituted C1-C6cycloalkyl, substituted C1-C6heterocycloalkyl, aryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of:
• C1-C6alkyl, C1-C6cycloalkyl, halogen, amino, substituted amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo or —(CH2)nCOOH, or heteroaryl optionally fused with a five-membered ring or substituted with one to five groups selected from a group consisting of:
• C1-C6alkyl, C1-C6cycloalkyl, halogen, amino, trifluoromethyl, cyano, hydroxyl, alkoxy, oxo, or —(CH2)nCOOH;
• n is 0-2, m is 0-2;
• or a pharmaceutically acceptable salt thereof;
• provided that R2 is not thienyl or substituted thienyl.